RecruitingNot ApplicableNCT06274268

Effect of Sarcopenia on the Occurrence of Toxicity Related to Anti-cancer Treatments

Effect of Sarcopenia on the Occurrence of Toxicity Related to Anti-cancer Treatments. Prospective Cohort Study

Sponsor

Centre Hospitalier Metropole Savoie

Enrollment

700 participants

Start Date

Jun 24, 2024

Study Type

INTERVENTIONAL

Conditions

Sarcopenia Oncology Physical Inactivity Toxicity Due to Chemotherapy

Summary

The goal of this clinical trial is to learn about the effect of sarcopenic status on the occurrence of treatment-related toxicity during the first course of anti-cancer treatment in several types of cancers. The main question it aims to answer is : Is sarcopenia a predictive marker for the occurrence of toxicity in the initial phase of cancer treatment? The evaluation will focus on the body composition of the participants, assessed by impedancemetry, and on their muscular performance by standardized physical tests.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Sarcopenia diagnostic test for people with oncology, physical inactivity, and other related conditions. The study is currently recruiting participants at 1 location.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIAGNOSTIC_TESTSarcopenia diagnostic test

the study-specific measurements for the assessment of sarcopenia (impedancemetry, grip strength and chair rise test) as well as the distribution of actimeters to patients.